

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Brolucizumab for treating diabetic macular oedema [ID3902]

Final Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals (brolucizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • BEMDA: Black and Ethnic Minority Diabetes Association • Black Health Agency for Equality • Diabetes Research & Wellness Foundation • Diabetes UK • Eyecare Trust • Fight for Sight • InDependent Diabetes Trust • Juvenile Diabetes Research Foundation (JDRF) • Macular Society • National Federation of the Blind of the UK • Network of Sikh Organisations • Organisation of Blind African Caribbeans • Royal National Institute of Blind People • SeeAbility • Sense • South Asian Health Foundation • Specialised Healthcare Alliance • Thomas Pocklington Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Clinical Diabetologists • Association of Optometrists • British and Irish Orthoptic Society • British Geriatrics Society • British Ophthalmic Anaesthesia Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Council for the Blind • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Alimera Sciences (fluocinolone acetonide intravitreal implant) • Allergan (dexamethasone intravitreal implant) • Bayer (aflibercept) • Novartis Pharmaceuticals (ranibizumab) • Organon Pharma (bevacizumab) • Pfizer (bevacizumab) • Roche (bevacizumab, faricimab) • Sanofi (aflibercept)

Final stakeholder list for the single technology appraisal of brolucizumab for treating diabetic macular oedema [ID3902]

Issue date: February 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • College of Optometrists • Health Lumen • Optical Confederation • Primary Care Diabetes Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society of Endocrinology • TREND UK • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Milton Keynes CCG • NHS Tees Valley CCG • Welsh Government 	<ul style="list-style-type: none"> • Thornton & Ross (bevacizumab) • Zentiva (bevacizumab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Eyes and Vision Group • Cochrane Metabolic & Endocrine Disorders Group • Cochrane UK • Eye Hope • Genomics England • Institute of Ophthalmology, University College London • MRC Clinical Trials Unit • National Eye Research Centre • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.